ComPlant (Shenzhen) Pharma Technology Ltd. – Trademark Portfolio

Entity Type: 99

ComPlant (Shenzhen) Pharma Technology Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include TRICYPLON. The owner is based in Shenzhen.

Suite 1702, Phase 1, Liuchuang Bldg,

Shenzhen 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

TRICYPLON
TRICYPLON
Registered 2022

Trademark Classifications

ComPlant (Shenzhen) Pharma Technology Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does ComPlant (Shenzhen) Pharma Technology Ltd. have?

ComPlant (Shenzhen) Pharma Technology Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does ComPlant (Shenzhen) Pharma Technology Ltd. file in?

ComPlant (Shenzhen) Pharma Technology Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are ComPlant (Shenzhen) Pharma Technology Ltd.'s most well-known trademarks?

ComPlant (Shenzhen) Pharma Technology Ltd.'s registered trademark portfolio includes well-known marks such as TRICYPLON. These are among 1 currently registered trademark in the portfolio.

What is ComPlant (Shenzhen) Pharma Technology Ltd.'s trademark registration success rate?

ComPlant (Shenzhen) Pharma Technology Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.